<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04918914</url>
  </required_header>
  <id_info>
    <org_study_id>Badar Kanwar</org_study_id>
    <nct_id>NCT04918914</nct_id>
  </id_info>
  <brief_title>Critical Care Results of SARS-CoV-2 ARDS by Dapsone and Standard COVID-19 Treatment</brief_title>
  <official_title>Off Label Use of Dapsone in SARS-CoV-2 Hospitalized Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hunt Regional Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hunt Regional Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Abstract Background: Clinicians in pulmonary critical care medicine and critical care&#xD;
      medicine considered dapsone administration to treat SARS-CoV-2 inflammasome. Dapsone is&#xD;
      useful in the molecular regulation of Nod-like receptor family pyrin domain-containing 3&#xD;
      (NLRP3).&#xD;
&#xD;
      Objective: To study the targeting of NLRP3 itself or up-/downstream factors of the NLRP3&#xD;
      inflammasome by dapsone must be responsible for its observed preventive effects, functioning&#xD;
      as a competitor.&#xD;
&#xD;
      Methods:&#xD;
&#xD;
      Patients who were on standard COVID-19 therapy are also after obtaining off label uses and&#xD;
      explanation of side effects are started on dapsone 100-200 mg daily along with Cimetadine 400&#xD;
      mg three times daily.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We are investigating in prospective ongoing non-randomized case study effects of addition of&#xD;
      dapsone 100-200 mg daily in addition to standardized recommended treatment versus a a cohort&#xD;
      of patient admitted at our institution since October 2020 versus a group that only received&#xD;
      standardized treatment. Our primary out comes are decrease in FIO2 requirement leading to&#xD;
      discharge from hospital and decrease in over all mortality between group treated with only&#xD;
      standardized recommended treat versus group with addition of dapsone and cimetadine.&#xD;
&#xD;
      An objective criteria of improvement, was used for effectiveness of therapy.&#xD;
&#xD;
      A. a reduction in the FIO2 requirement and&#xD;
&#xD;
      B. a decrease in the progression of hypoxia. We treated the patients with standard COVID-19&#xD;
      ARDS treatment with dapsone 100 mg to target NLRP3 inflammasomes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 18, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Addition of dapsone to COVID19 patient treated with standard treatment</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Critical Care Results of SARS-CoV-2 ARDS by Dapsone and Standard COVID-19 Treatment</measure>
    <time_frame>1 year</time_frame>
    <description>1. Decrease in overall mortality between groups treated with standardized recommended composite therapy for COVID-19 versus group of Standardized therapy plus addition of dapson and cimedatine</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>SARS-CoV-2</condition>
  <condition>Hypoxia</condition>
  <condition>ARDS</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapsone 100 MG</intervention_name>
    <description>Dapsone 100-200 md orally daily, along with Cimetadine 400 mg PO TID</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        1. All, PCR confirmed cases of COVID-19&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        1. Only consenting consenting patients&#xD;
&#xD;
        -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kanwar</last_name>
    <phone>4694228931</phone>
    <email>bkanwar2@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hunt Regional Medical Center</name>
      <address>
        <city>Greenville</city>
        <state>Texas</state>
        <zip>75401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Badar Kanwar</last_name>
      <phone>469-422-8931</phone>
      <email>BKANWAR2@YAHOO.COM</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>May 27, 2021</study_first_submitted>
  <study_first_submitted_qc>June 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 9, 2021</study_first_posted>
  <last_update_submitted>June 7, 2021</last_update_submitted>
  <last_update_submitted_qc>June 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hunt Regional Medical Center</investigator_affiliation>
    <investigator_full_name>Badar Kanwar</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Hypoxia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dapsone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

